Spacing of TNF-blocker Injections in Rheumatoid Arthritis Study
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Remission is nowadays the recommended therapeutic objective in rheumatoid arthritis. Once
this objective is achieved thanks to TNF-blockers, the optimal therapeutic strategy remains
unclear, either therapeutic maintenance or progressive DMARD tapering (with a non quantified
risk of disease flare).
STRASS is a 2-arm randomized controlled trial aiming to compare these 2 strategies (DMARD
maintenance or progressive spacing of TNF-blocker injections) in terms of remission
maintenance, relapse risk, safety issues and economic consequences during 18 months.
The inclusion period is 18 months, between September 2008 and February 2010.